ClinConnect ClinConnect Logo
Search / Trial NCT06236594

Application of Multimodal Endoscopic Functional Imaging Technology in the Diagnosis of Common Gastrointestinal Diseases

Launched by BEIJING 302 HOSPITAL · Jan 24, 2024

Trial Information

Current as of July 07, 2025

Recruiting

Keywords

Endoscopic Laser Speckle Imaging Multispectral Blood Oxygen Imaging Gastrointestinal Lesions Early Diagnosis Gastrointestinal Tumors

ClinConnect Summary

This clinical trial is studying a new imaging technology called multimodal endoscopic functional imaging. This technology aims to help doctors better see and understand common gastrointestinal diseases, such as chronic gastritis, gastric polyps, and colon cancer. By using advanced imaging techniques, the study hopes to improve the early detection of gastrointestinal tumors and assess the health of the tissues and blood vessels in the digestive system.

If you are between 18 and 80 years old and have a diagnosed or suspected gastrointestinal condition, you might be eligible to participate. However, individuals with severe heart or brain diseases, certain mental health issues, bleeding disorders, or those who are pregnant or breastfeeding cannot join. Participants will undergo endoscopic procedures, which involve using a thin tube to look inside the digestive tract, and they will need to sign a consent form to ensure they understand the study. This trial is currently looking for volunteers, and it represents an important step in improving the diagnosis and treatment of gastrointestinal diseases.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age: 18-80 years old, gender is not limited
  • 2. Diagnosed or suspected of one of the following common gastrointestinal mucosal diseases: Chronic non-atrophic gastritis, chronic atrophic gastritis, gastric polyps, early gastric cancer, advanced gastric cancer, colon polyps, colon melanosis, inflammatory bowel disease, early colon cancer, advanced colon cancer
  • 3. Sign the informed consent form -
  • Exclusion Criteria:
  • 1. Combined with cardiovascular and cerebrovascular diseases, or severe impairment of liver, kidney and hematopoietic system;
  • 2. mentally ill;
  • 3. the presence of bleeding disorders;
  • 4. Platelet count\<50×10\^9/L;
  • 5. Inability to tolerate or cooperate with endoscopy;
  • 6. Patients with serious complications, such as severe infection, gastrointestinal bleeding, obstruction, perforation, etc.;
  • 7. Pregnant or lactating women.
  • 8. Refuse to sign the informed consent form

About Beijing 302 Hospital

Beijing 302 Hospital is a leading medical institution in China, renowned for its advanced clinical research and comprehensive healthcare services. As a sponsor of clinical trials, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and innovation. With a multidisciplinary team of experienced researchers and healthcare professionals, Beijing 302 Hospital focuses on a wide range of therapeutic areas, employing state-of-the-art facilities and methodologies to ensure the highest standards of trial integrity and patient safety. The hospital's dedication to ethical practices and collaboration fosters an environment conducive to groundbreaking research and the development of new treatment modalities.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Yan Liu

Principal Investigator

Beijing 302 Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported